Navigate Fool.com
Will MELA beat
the market?

MELA Sciences


Community Rating: 1 Star: Ominous

0.54 0.02 (2.90%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.54
Previous Close $0.52
Daily Range $0.52 - $0.55
52-Week Range $0.51 - $1.39
Market Cap $25.8M
P/E Ratio -0.88
Dividend (Yield) $0.00 (0.0%)
Volume 113,126
Average Daily Volume 548,159
Current FY EPS -$0.39

How do you think MELA
will perform against the market?

Top MELA Bull/Bear Pitches


JonPon (0)
Submitted September 10, 2010

With the accuracy of the MELAFind device being statistically significant in comparison with dermatologists and with it's non-invasive nature it is sure to be a winning device.

1 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted September 16, 2011

MELA is enjoying a nice double this month, courtesy of receiving a CE Mark designation for MelaFind in Europe. I was too cautious to red thumb then in the heat of enthusiasm last week, but it looks li … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

Buy, Sell, or Hold: MELA Sciences

Do the benefits here outweigh the risks?

Blue Chips And Investment Trusts Among This Fund's Top Picks

The Barclays Triggers More Insider Buying

Market Close: Today’s Big Winners & Losers (OSIR, END, APP, HCI, PTEK, RDIB, MELA, OPXA, ACUR, RWC)

How Global Growth of Cancer Can Make You Money

This Just In: Upgrades and Downgrades

Everybody's down on Dendreon, lately.

2 Stocks Stopping the Presses

These companies made big headlines -- what does it mean to you?

Here's What George Soros Has Been Buying and Selling

Take a peek at what the smartest investors are doing.

This Just In: Upgrades and Downgrades

ThinkEquity says Intuitive Surgical is a no-brainer. Is it right?

Mark Your Calendars, Biotech Investors

Cell Therapeutics' advisory panel meet ought to be entertaining.

See More MELA News...




Healthcare Information Services

MELA Sciences (MELA) Description

A medical device company which focuses on designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. Website: http://www.melasciences.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks